Compare GLDD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | DRUG |
|---|---|---|
| Founded | 1890 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 707.1M |
| IPO Year | 2007 | 2020 |
| Metric | GLDD | DRUG |
|---|---|---|
| Price | $16.96 | $69.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $17.00 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 1.5M | 81.6K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $3.79 | N/A |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | $15.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.51 | $23.18 |
| 52 Week High | $16.99 | $123.75 |
| Indicator | GLDD | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 36.51 |
| Support Level | $14.60 | $49.47 |
| Resistance Level | $16.99 | $84.29 |
| Average True Range (ATR) | 0.04 | 4.10 |
| MACD | -0.09 | -1.10 |
| Stochastic Oscillator | 80.00 | 8.74 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.